Rapport Therapeutics, Inc. 8-K

What Happened Rapport Therapeutics, Inc. announced its financial results and business highlights for the quarter and year ended December 31, 2025 on March 10, 2026. The company furnished a press release with those results as Exhibit 99.1 to the Form 8-K (Item 2.02 reporting results of operations and financial condition; Item 9.01 lists the exhibit). The report was signed by Troy Ignelzi, Chief Financial Officer.

Key Details

• Announcement date: March 10, 2026.
• Reporting period: quarter and year ended December 31, 2025.
• Press release with results furnished as Exhibit 99.1 to the Form 8-K.
• Form 8-K Items: 2.02 (results of operations and financial condition) and 9.01 (exhibits).

Why It Matters This filing signals that the company has released its quarterly and full-year financial results—information that can affect stock valuation and investor decisions. Retail investors should review the furnished press release (Exhibit 99.1) for specific metrics such as revenue, net loss/profit, cash position, and any commentary on business progress or guidance. The 8-K itself furnishes the release; for detailed financial tables and management commentary, check the press release and any subsequent SEC filings.